Literature DB >> 34173107

Dynamics of Antibodies to Various Antigens of the SARS-CoV-2 Coronavirus in Patients with Confirmed COVID-19 Infection.

A V Aleshkin1, L I Novikova1, S S Bochkareva1, S Yu Kombarova1, Yu S Lebedin2, A M Vorob'ev3, E R Mekhtiev1, E R Zul'karneev4, A I Laishevtsev4, A V Karaulov1.   

Abstract

The presence of IgG and IgM antibodies in the venous blood of 76 patients with confirmed COVID-19 infection was determined by ELISA using Russian test systems. Different levels of IgM antibodies to N-protein and receptor binding domain of the Spike protein (RBD) were revealed. The dynamics of IgG antibodies to the whole virion antigen and recombinant antigens showed high values on weeks 4-5 of the disease. The level of IgG antibodies to Nprotein remained low throughout the observation period. The characteristic dynamics of IgG measured using test systems with sorbed whole virion or recombinant spike proteins reflects the duration of the disease.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antibodies; dynamics; humoral immunity

Year:  2021        PMID: 34173107      PMCID: PMC8233179          DOI: 10.1007/s10517-021-05200-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  7 in total

1.  Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019.

Authors:  Fei Xiang; Xiaorong Wang; Xinliang He; Zhenghong Peng; Bohan Yang; Jianchu Zhang; Qiong Zhou; Hong Ye; Yanling Ma; Hui Li; Xiaoshan Wei; Pengcheng Cai; Wan-Li Ma
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

2.  Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma.

Authors:  Christian Bundschuh; Margot Egger; Kurt Wiesinger; Christian Gabriel; Martin Clodi; Thomas Mueller; Benjamin Dieplinger
Journal:  Clin Chim Acta       Date:  2020-06-08       Impact factor: 3.786

Review 3.  SARS-CoV-2 Vaccines: Status Report.

Authors:  Fatima Amanat; Florian Krammer
Journal:  Immunity       Date:  2020-04-06       Impact factor: 31.745

4.  SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.

Authors:  Giovanni Salvatori; Laura Luberto; Mariano Maffei; Luigi Aurisicchio; Giuseppe Roscilli; Fabio Palombo; Emanuele Marra
Journal:  J Transl Med       Date:  2020-06-03       Impact factor: 5.531

5.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

6.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.

Authors:  Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler
Journal:  Cell       Date:  2020-03-09       Impact factor: 41.582

7.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Authors:  Wanbo Tai; Lei He; Xiujuan Zhang; Jing Pu; Denis Voronin; Shibo Jiang; Yusen Zhou; Lanying Du
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.